Successes and shortcomings of polio eradication: A transmission modeling analysis

American Journal of Epidemiology

Volumn 177, Issue 11, 2013, Pages 1236-1245

  Mayer, Bryan T ^b   Eisenberg, Joseph N S ^b   Henry, Christopher J ^b   Gomes, M Gabriela M ^b   Ionides, Edward L ^b   Koopman, James S ^a  

^a Epidemiology Research Unit   (United States)

^b NONE

Author keywords

immunity; immunization programs; infectious disease transmission; mathematical model; poliomyelitis; poliovirus; poliovirus vaccines; vaccination

Indexed keywords

ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE;

ADULT; DISEASE CONTROL; DISEASE PREVALENCE; DISEASE TRANSMISSION; GLOBAL PERSPECTIVE; HEALTH POLICY; HEALTH SERVICES; IMMUNITY; PATHOGEN; POLIOMYELITIS; VACCINATION; VIRAL DISEASE;

ARTICLE; DISEASE ERADICATION; EPIDEMIC; HUMAN; IMMUNIZATION; MATHEMATICAL MODEL; NONHUMAN; POLIOMYELITIS; POLIOMYELITIS VIRUS; PREVALENCE; SANITATION; TRANSMISSION MODEL; VACCINATION; VIRAL CLEARANCE; VIRUS TRANSMISSION;

IMMUNITY; IMMUNIZATION PROGRAMS; INFECTIOUS DISEASE TRANSMISSION; MATHEMATICAL MODEL; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINES; VACCINATION;

DISEASE ERADICATION; HUMANS; MASS VACCINATION; MODELS, IMMUNOLOGICAL; POLIOMYELITIS; POLIOVIRUS VACCINE, ORAL;

POLIOVIRUS;

EID: 84878576879     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kws378     Document Type: Article

References (33)

1. Polio Global Eradication Initiative. Infected Countries. Geneva, Switzerland:World Health Organization; 2010. (http://www.polioeradication.org/ Infectedcountries.aspx). (Accessed May 1, 2012).
2. Abbink F, Buisman AM, Doornbos G, et al. Poliovirusspecific memory immunity in seronegative elderly people does not protect against virus excretion. J Infect Dis. 2005;191(6): 990-999.
3. Bass JW, Halstead SB, Fischer GW, et al. Oral polio vaccine. Effect of booster vaccination one to 14 years after primary series. JAMA. 1978;239(21):2252-2255.
4. Conyn-Van Spaendonck MA, de Melker HE, Abbink F, et al. Immunity to poliomyelitis in the Netherlands. Am J Epidemiol. 2001;153(3):207-214.
5. Green MS, Handsher R, Cohen D, et al. Age differences in immunity against wild and vaccine strains of poliovirus prior to the 1988 outbreak in Israel and response to booster immunization. Vaccine. 1993;11(1):75-81.
6. Grotto I, Handsher R, Gdalevich M, et al. Decline in immunity to polio among young adults. Vaccine. 2001;19(30): 4162-4166.
7. Lapinleimu K, Stenvik M. Experiences with polio vaccination and herd immunity in Finland. Dev Biol Stand. 1981; 47:241-246.
8. Majori S, Baldo V, Poli A, et al. Immunity to poliovirus among children and the elderly in north-east Italy. J Prev Med Hyg. 2006;47(1):12-15.
9. Murph JR, Grose C, McAndrew P, et al. Sabin inactivated trivalent poliovirus vaccine: first clinical trial and seroimmunity survey. Pediatr Infect Dis J. 1988;7(11): 760-765.
10. Nishio O, Ishihara Y, Sakae K, et al. The trend of acquired immunity with live poliovirus vaccine and the effect of revaccination: follow-up of vaccinees for ten years. J Biol Stand. 1984;12(1):1-10.
11. Schoub BD, Blackburn NK, McAnerney JM. Seroprevalence to polio in personnel at a virology institute. J Infect. 2001; 43(2):128-131.
12. Nates SV, Martinez LC, Barril PA, et al. Long-lasting poliovirus-neutralizing antibodies among Argentinean population immunized with four or five oral polio vaccine doses 1 month to 19 years previously. Viral Immunol. 2007; 20(1):3-10.
13. Rousseau WE, Noble GR, Tegtmeier GE, et al. Persistence of poliovirus neutralizing antibodies eight years after immunization with live, attenuated-virus vaccine. N Engl J Med. 1973;289(25):1357-1359.
14. Trivello R, Farisano G, Bonello C, et al. Immunity status to poliovirus in Veneto region (north-east Italy). A seroepidemiological survey. Ann Clin Lab Sci. 1994;24(6): 542-547.
15. Triassi M, Ribera G, Barruffo L, et al. Persistence of immunity to poliomyelitis among a southern population that received four doses of OPV 5 to over 15 years before. Eur J Epidemiol. 1996;12(1):5-8.
16. Sutter RW, Suleiman AJM, Malankar P, et al. Trial of a supplemental dose of four poliovirus vaccines. N Engl J Med. 2000;343(11):767-773.
17. Alexander JP Jr, Gary HE Jr, Pallansch MA. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J Infect Dis. 1997;175(suppl 1):S176-S182.
18. Swartz TA, Green MS, Handscher R, et al. Intestinal immunity following a combined enhanced inactivated polio vaccine/oral polio vaccine programme in Israel. Vaccine. 2008;26(8): 1083-1090.
19. Buisman AM, Abbink F, Schepp RM, et al. Preexisting poliovirus-specific IgA in the circulation correlates with protection against virus excretion in the elderly. J Infect Dis. 2008;197(5):698-706.
20. Grassly NC, Jafari H, Bahl S, et al. Asymptomatic wild-type poliovirus infection in India among children with previous oral poliovirus vaccination. J Infect Dis. 2010;201(10): 1535-1543.
21. Sutter RW, Patriarca PA, Brogan S, et al. Outbreak of paralytic poliomyelitis in Oman: evidence for widespread transmission among fully vaccinated children. Lancet. 1991;338(8769): 715-720.
22. Fine PE. Polio: measuring the protection that matters most. J Infect Dis. 2009;200(5):673-675.
23. Grassly NC, Jafari H, Bahl S, et al. Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India. J Infect Dis. 2009;200(5): 794-801.
24. Henry JL, Jaikaran ES, Davies JR, et al. A study of poliovaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine. J Hyg (Lond). 1966;64(1):105-120.
25. Grassly NC, Jafari H, Bahl S, et al.Waning intestinal immunity after vaccination with oral poliovirus vaccines in India. J Infect Dis. 2012;205(10):1554-1561.
26. Fine PE, Carneiro IA. Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative. Am J Epidemiol. 1999; 150(10):1001-1021.
27. Schenzle D. An age-structured model of pre-and postvaccination measles transmission. IMA J Math Appl Med Biol. 1984;1(2):169-191.
28. Rohani P, Zhong X, King AA. Contact network structure explains the changing epidemiology of pertussis. Science. 2010;330(6006):982-985.
29. Kew O. Reaching the last one per cent: progress and challenges in global polio eradication. Curr Opin Virol. 2012;2(2):188-198.
30. Gomes MG, White LJ, Medley GF. Infection, reinfection, and vaccination under suboptimal immune protection: epidemiological perspectives. J Theor Biol. 2004;228(4): 539-549.
31. Herremans TMPT, Reimerink JHJ, Buisman AM, et al. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J Immunol. 1999;162(8):5011-5018.
32. Okayasu H, Sutter RW, Czerkinsky C, et al. Mucosal immunity and poliovirus vaccines: impact on wild poliovirus infection and transmission. Vaccine. 2011;29(46):8205-8214.
33. Duintjer Tebbens RJ, Pallansch MA, Kew OM, et al. A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future. Am J Epidemiol. 2005;162(4): 358-372.